Literature DB >> 31286591

Fulminant hepatitis as an immune-related adverse event after nivolumab treatment.

Osamu Inamori1, Aya Miyagawa-Hayashino1, Akihisa Ueno2, Fumiya Hongo2, Yuta Sonobe1, Tomohito Hojo1, Eiichi Konishi1.   

Abstract

Entities:  

Keywords:  fulminant hepatitis; immune-related adverse event; nivolumab; treatment

Mesh：

Substances：

Year:  2019        PMID： 31286591     DOI： 10.1111/pin.12812

Source DB:  PubMed          Journal:  Pathol Int        ISSN： 1320-5463            Impact factor:   2.534


× No keyword cloud information.
  5 in total

1.  Hepatobiliary and Pancreatic Adverse Events.

Authors:  Hao Chi Zhang; Lan Sun Wang; Ethan Miller
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 2.  Hepatotoxicity Induced by Biological Agents: Clinical Features and Current Controversies.

Authors:  Nelia Hernandez; Fernando Bessone
Journal:  J Clin Transl Hepatol       Date:  2022-01-25

3.  Morphology of tumor and nontumor tissue in liver resection specimens for hepatocellular carcinoma following nivolumab therapy.

Authors:  Camila C Simoes; Swan N Thung; Maria Isabel Fiel; Max W Sung; Myron E Schwartz; Stephen C Ward
Journal:  Mod Pathol       Date:  2020-09-28       Impact factor: 7.842

4.  Rescue liver re-transplantation after graft loss due to severe rejection in the setting of pre-transplant nivolumab therapy.

Authors:  Yalda Dehghan; Gabriel T Schnickel; Mojgan Hosseini; Adam M Burgoyne; Veeral H Ajmera; Gerald P Morris; Michel H Mendler; Justin R Parekh; Farid Abushamat; Irine Vodkin; Yuko Kono
Journal:  Clin J Gastroenterol       Date:  2021-10-13

Review 5.  Application of artificial liver in immune-related liver injury induced by immune checkpoint inhibitor: Case reports and review of the literature.

Authors:  Xuewei Li; Lina Ji; Xiaofang Li; Dong Sun; Wenhui Yang
Journal:  Front Immunol       Date:  2022-09-02       Impact factor: 8.786
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.